Latest news for CeCors (OTC:CEOS) Stock

CeCors Inc along with its subsidiaries is engaged in the research and development, production, and commercialization of therapeutic and medicinal entheogenic, adaptogenic, and nootropic ingredients and formulations for its premium functional product lines which are developed by its mycology and botany experts. The company is also engaged in the scientific development of patentable technologies pertaining to the composition, bioavailability, and targeted delivery of entheogen-based therapeutics.

CeCors Inc

CeCors reports Q2 revenue of $1.32M

CEOS

Small Cap

Press Releases

VETCOMM Achieves Remarkable Growth: Expands Workforce by 33%, Welcomes Ten New Sales Professionals, Including Two from the Department of Defense's SkillBridge Program

VetComm Urges Action: The Unsettling Impact of Free College on Military Recruitment Threatens National Security

News

VETCOMM's New Conquer Brand No-Nicotine Pouches Seeks to Carve Out a Share of the Billion-Dollar Market

VETCOMM's Subscription Sales Surge Past $786,000 in 2023; CEOS Prepares for a Record First Quarter in 2024

VETCOMM Set to Increase Sales Volume Through New Partnership with MVA - A National Call Center

Earnings

CEOS Reports $1.03M in Q1 Sales; VETCOMM Drives Growth and Sets Stage for Strong Q2

VETCOMM Strengthens Shareholder Value and Veteran Integration Through Successful DoD SkillBridge Transitions

CEOS Announces the Introduction of New VETCOMM App to Simplify Veteran Support and Increase Sales in Billion Dollar Veterans Benefits Market

VETCOMM Reduces Costs and Improves Service for Veterans by Moving Call Center In-House

CEOS Engages Exclusive Key Congressional Leaders to Strengthen Market Position and Become the Category Leader in Billion Dollar Veterans Benefits Market

CeCors

Comments

CeCors

News

Latest news for CeCors (OTC:CEOS) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga